| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 14.62 | 4.45 | 8.00 | 12.26 | 14.83 | 9.37 | 80.21 | 0.46 | 1.80 | 3.04 | 1.54 | 0.96 |
| Quick Ratio | 14.62 | 4.45 | 8.00 | 12.26 | 14.83 | 9.37 | 80.21 | 0.46 | 1.80 | 3.04 | 1.54 | 0.96 |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE | -66.33% | -225.15% | -115.74% | -111.83% | -60.38% | -56.31% | -12.97% | 162.54% | -430.50% | -42.24% | -236.14% | — |
| ROA | -61.05% | -174.56% | -101.27% | -102.71% | -56.31% | -50.31% | -12.81% | -293.98% | -221.60% | -29.04% | -85.29% | — |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — | — |
| Book Value / Share | 2.19 | 1.18 | 2.84 | 4.74 | 11.87 | — | — | — | — | — | — | — |
Relmada Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel therapies for central nervous system disorders and oncology indications. Its primary efforts center on NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel designed for the treatment of non-muscle invasive bladder cancer, particularly in high-risk BCG-unresponsive and intermediate-risk patients, addressing significant unmet needs in urologic oncology. The company is also advancing programs in CNS diseases, including esmethadone (REL-1017), an N-methyl-D-aspartate receptor antagonist serving as an oral agent for depression, and sepranolone, a GABAA-modulating compound targeted at compulsivity-related disorders such as Prader-Willi syndrome. Relmada Therapeutics Inc. operates within the biotechnology sector, emphasizing chemical entities and innovative drug delivery systems to improve patient outcomes in areas with limited treatment options. Headquartered in Coral Gables, Florida, and founded in 2012, the company remains committed to advancing its pipeline through clinical development and regulatory interactions in the healthcare market.